Evidence map›Paper›PMID 38370292›Full record

Trial reportOpen forum infectious diseases2024

Hypoxemic Respiratory Failure and Coccidioidomycosis-Associated Acute Respiratory Distress Syndrome.

Arash Heidari, Simmer Kaur, Skyler J Pearson, Augustine Munoz, Harleen Sandhu, Gursimran Mann, Michael Schivo, Amir A Zeki, Derek J Bays, Machelle Wilson and 3 more

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Arash HeidariDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Bakersfield, California, USA.
Simmer KaurValley Fever Institute, Bakersfield, California, USA.
Skyler J PearsonUniversity of California-Davis Medical Center, Sacramento, CA, USA.
Augustine MunozValley Fever Institute, Bakersfield, California, USA.
Harleen SandhuDivision of Infectious Diseases, Department of Internal Medicine, Kern Medical, Bakersfield, California, USA.
Gursimran MannUniversity of California-Davis Medical Center, Sacramento, CA, USA.
Michael SchivoDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UC Davis Lung Center, University of California Davis Medical Center, Sacramento, CA, USA.
Amir A ZekiDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UC Davis Lung Center, University of California Davis Medical Center, Sacramento, CA, USA.
Derek J BaysDivision of Infectious Diseases, Department of Internal Medicine, University of California Davis Medical Center, Sacramento, CA, USA.
Machelle WilsonDepartment of Public Health Sciences, University of California- Davis, Davis, California, USA.
Timothy E AlbertsonDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UC Davis Lung Center, University of California Davis Medical Center, Sacramento, CA, USA.
Royce JohnsonDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Bakersfield, California, USA.
George R ThompsonDivision of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, UC Davis Lung Center, University of California Davis Medical Center, Sacramento, CA, USA.

Funding

UC Davis Environmental Health Sciences Core CenterP30ES023513 · NIEHS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Ameer Taha · 2015 to 2026
$26.0M
Statin Lipophilicity as a Determinant of Drug Airway Distribution: A Pilot Study to Identify the Most Potent Statin(s) for the Treatment of Severe Asthma.R03AI139648 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2019 to 2020
$157k
Isoprenoid Biology in Asthma: Proof-of-Principle and Method DevelopmentR03HL148486 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI ZEKI, AMIR A. · 2019 to 2020
$157k
NIEHS NIH HHS P30 ES023513
6 · The paper itself

Abstract

Background: Severe coccidioidomycosis presenting with respiratory failure is an uncommon manifestation of disease. Current knowledge of this condition is limited to case reports and small case series. Methods: A retrospective multicenter review of patients with coccidioidomycosis-associated acute respiratory distress syndrome (CA-ARDS) was conducted. It assessed clinical and laboratory variables at the time of presentation, reviewed the treatment course, and compared this cohort with a national database of patients with noncoccidioidomycosis ARDS. Survivors and nonsurvivors of coccidioidomycosis were also compared to determine prognostic factors. Results: In this study, CA-ARDS (n = 54) was most common in males, those of Hispanic ethnicity, and those with concurrent diabetes mellitus. As compared with the PETAL network database (Prevention and Early Treatment of Acute Lung Injury; n = 1006), patients with coccidioidomycosis were younger, had fewer comorbid conditions, and were less acidemic. The 90-day mortality was 15.4% for patients with coccidioidomycosis, as opposed to 42.6% ( Conclusions: CA-ARDS is an uncommon but morbid manifestation of infection. When compared with a national database, the overall mortality appears favorable vs other causes of ARDS. Patients with CA-ARDS had a low overall mortality but required prolonged antifungal therapy. The utility of corticosteroids in this condition remains unconfirmed.

Indexed as

ARDSCoccidioidesfungal pneumoniaglucocorticoidssteroids

Identifiers

PMID38370292
PMCPMC10873137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.